Moberg Pharma
Pharmaceutical company developing and commercializing treatments for nail fungus.
MOB | ST
Overview
Corporate Details
- ISIN(s):
- SE0011311596 (+3 more)
- LEI:
- 549300XFXK7DVGDRP410
- Country:
- Sweden
- Address:
- Gustavslundsvagen 42, 167 51 Stockholm
- Website:
- https://www.mobergpharma.com/
- Sector:
- Manufacturing
Description
Moberg Pharma is a pharmaceutical company that develops and commercializes proprietary medical products, focusing on innovative drug delivery of proven compounds. The company's primary asset is MOB-015, a topical formulation for the treatment of onychomycosis (nail fungus). MOB-015 has demonstrated high fungal cure rates in Phase 3 clinical trials and has received market approval in multiple European countries. It is commercialized under the brand name Terclara® in Sweden and Norway, where it has achieved market leadership. Moberg Pharma's business model aims for lower development risk and faster market entry than traditional pharmaceutical development. The company's strategic goal is to establish MOB-015 as the leading global treatment for nail fungus.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2020-03-23 21:00 |
Moberg Pharma enters financing agreement of up to SEK 216 million for further i…
|
English | PDF • 202.7 KB | ||
| 2020-03-23 21:00 |
Moberg Pharma ingår finansieringsavtal om upp till 216 MSEK för fortsatt satsni…
|
Swedish | PDF • 179.3 KB | ||
| 2020-02-11 08:00 | Swedish | PDF • 856.6 KB | |||
| 2020-02-11 08:00 | English | PDF • 868.4 KB | |||
| 2020-02-04 08:00 |
Moberg Pharma’s Interim report to be published on February 11 - Invitation to t…
|
English | PDF • 123.4 KB | ||
| 2020-02-04 08:00 |
Moberg Pharmas delårsrapport presenteras 11 februari - Inbjudan till telefonkon…
|
Swedish | PDF • 123.0 KB | ||
| 2020-01-22 08:00 |
Expertutvärdering förklarar Fas 3 resultat och ger starkt stöd för MOB-015
|
Swedish | PDF • 122.4 KB | ||
| 2020-01-22 08:00 |
Expert evaluation clarifies Phase 3 results and provides strong support for MOB…
|
English | PDF • 161.3 KB | ||
| 2020-01-14 08:30 |
Skatteverket meddelar fördelning av anskaffningsutgift för aktier med anledning…
|
Swedish | PDF • 87.7 KB | ||
| 2020-01-14 08:30 |
The Swedish Tax Agency has published a notification on distribution of the acqu…
|
English | PDF • 97.9 KB | ||
| 2019-12-17 14:51 | English | PDF • 35.4 KB | |||
| 2019-12-16 12:43 | English | PDF • 35.6 KB | |||
| 2019-12-13 12:51 | English | PDF • 35.4 KB | |||
| 2019-12-12 08:00 |
Moberg Pharma comments on the results of the North American Phase 3 study with …
|
English | PDF • 118.1 KB | ||
| 2019-12-12 08:00 |
Moberg Pharma kommenterar resultaten i den nordamerikanska fas 3 studien med MO…
|
Swedish | PDF • 115.9 KB |
Automate Your Workflow. Get a real-time feed of all Moberg Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Moberg Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Moberg Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-11-11 | Mark Beveridge | Other | Buy | 3,000 | 17,730.00 SEK |
| 2021-11-10 | Mark Beveridge | Other | Buy | 3,000 | 17,310.00 SEK |
| 2021-11-09 | Mark Beveridge | Other | Buy | 5,000 | 29,800.00 SEK |
| 2021-02-10 | Cindy Wong | Other | Buy | 5,000 | 31,675.00 SEK |
| 2021-02-09 | Cindy Wong | Other | Buy | 5,000 | 30,800.00 SEK |
Peer Companies
